NCT01522833

Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 27 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.

Conditions

• Non Small Cell Lung Cancer

Timeline

• Start date: 2012-10-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2012-02-01
• Last updated: 2016-03-07

Locations

1 site across 1 country: United States